RRx-001 Sequentially With a Platinum Doublet or a Platinum Doublet in Third-Line or Beyond in Patients With Small Cell Lung Cancer

PHASE3TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

December 24, 2018

Primary Completion Date

August 11, 2022

Study Completion Date

March 1, 2024

Conditions
Carcinoma, Small Cell Lung
Interventions
COMBINATION_PRODUCT

RRx-001 + eLOOP Device

RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device

DRUG

Cisplatin/carboplatin plus etoposide

Standard of care platinum doublet chemotherapy

Trial Locations (18)

21201

University of Maryland Marlene and Stewart Greenbaum Comprehensive Cancer Center, Baltimore

32763

Mid Florida Hematology and Oncology Center, Orange City

32804

AdventHealth Hematology and Oncology, Orlando

33612

H. Lee Moffitt Cancer Center & Research Institute, Inc., Tampa

37909

Tennessee Cancer Specialists, Knoxville

39213

University of Mississippi Medical Center, Jackson

40202

Norton Cancer Institute, Norton Healthcare Pavilion, Louisville

60612

Rush University Medical Center, Chicago

63110

Washington University School of Medicine - Siteman Cancer Center, St Louis

66205

The University of Kansas Cancer Center, Westwood

66606

Cotton O'Neil Clinical Research Center.Hematology & Oncology, Topeka

68124

Oncology Hematology West PC dba Nebraska Cancer Specialists, Omaha

73104

Stephenson Cancer Center, Oklahoma City

75701

HOPE Cancer Center of East Texas, Tyler

77090

Millennium Oncology, Houston

80210

Centura Health Research Center, Denver

84106

Utah Cancer Specialist, Salt Lake City

03756

Dartmouth-Hitchcock Medical Center, Lebanon

Sponsors

Lead Sponsor

All Listed Sponsors
lead

EpicentRx, Inc.

INDUSTRY